Revised criteria for the diagnosis and staging of Alzheimer’s disease
Clifford R. Jack(Mayo Clinic), Marı́a C. Carrillo(Alzheimer's Association), Carole Ho(Denali Therapeutics (United States)), Luca Pani(University of Miami), Billy Dunn(Center for Drug Evaluation and Research), Philip Scheltens(Amsterdam University Medical Centers), Michael S. Rafii(University of Southern California), José Luís Molinuevo(Pasqual Maragall Foundation), Oskar Hansson(Eli Lilly (United States)), William J. Jagust(Lawrence Berkeley National Laboratory), Teresa Buracchio(United States Food and Drug Administration), Eric McDade(University of Pittsburgh), Thomas G. Beach(Banner Sun Health Research Institute), Charlotte E. Teunissen(Amsterdam Neuroscience), Eric Siemers(Eli Lilly (United States)), Ozioma C. Okonkwo(University of Wisconsin–Madison), Ana Graf(Novartis (Switzerland)), Reisa A. Sperling(Harvard University), Scott J. Andrews(Takeda (United States)), Heather M. Snyder(Alzheimer's Association)
Cited by 165
Related Papers
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|18.9k
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Consistent resting-state networks across healthy subjects
|Proceedings of the National Academy of Sciences|2006|4.4k